The NR3B subunit does not alter the anesthetic sensitivities of recombinant N-methyl-D-aspartate receptors. 2005

Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
*Division of Anesthesiology, Niigata University Graduate School of Medical and †Dental Sciences; Department of Cellular Neurobiology, Brain Research Institute, Niigata University, Niigata, Japan.

The N-methyl-D-aspartate (NMDA) receptor NR3B subunit co-assembles with NR1 and NR2 subunits to form a receptor complex with distinct channel properties. In the present study, we investigated the effects of co-expression of the NR3B subunit on the anesthetic sensitivities of NMDA receptors for NR1/NR2 channels expressed in Xenopus oocytes. Although the NR3B subunit prominently reduced the current amplitude of NR1/NR2A-B channels, the sensitivities of NR1/NR2A-B channels to Mg2+, ketamine, isoflurane, nitrous oxide, and ethanol were not altered by coexpression of the NR3B subunit. These results suggest that the anesthetic sensitivities of NMDA receptors do not depend on the presence or absence of the NR3 subunit. Mutations of two amino acid residues in the NR3B subunit at positions homologous to the N and N + 1 sites in the NR1 and NR2 subunits, which constitute the blocking sites for Mg2+ and ketamine, did not affect the sensitivities of NR1/NR2B/NR3B channels to Mg2+, ketamine and isoflurane. Thus, the amino acid residues at the N and N + 1 sites in NR3 subunits are unlikely to be involved in the formation of channel blocking sites in NR1/NR2/NR3 channels.

UI MeSH Term Description Entries
D007649 Ketamine A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone,CI-581,Calipsol,Calypsol,Kalipsol,Ketalar,Ketamine Hydrochloride,Ketanest,Ketaset,CI 581,CI581
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009609 Nitrous Oxide Nitrogen oxide (N2O). A colorless, odorless gas that is used as an anesthetic and analgesic. High concentrations cause a narcotic effect and may replace oxygen, causing death by asphyxia. It is also used as a food aerosol in the preparation of whipping cream. Laughing Gas,Nitrogen Protoxide,Gas, Laughing,Oxide, Nitrous
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002492 Central Nervous System Depressants A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents). CNS Depressants,Depressants, CNS
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
September 1994, Molecular pharmacology,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
January 2009, Dementia and geriatric cognitive disorders,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
March 2000, Epilepsy research,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
August 1994, European journal of pharmacology,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
May 2010, The Journal of biological chemistry,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
September 1997, Proceedings of the National Academy of Sciences of the United States of America,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
November 1994, Proceedings of the National Academy of Sciences of the United States of America,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
December 1996, Molecular pharmacology,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
July 2008, Neuroscience,
Tomohiro Yamakura, and Ahmed R Askalany, and Andrey B Petrenko, and Tatsuro Kohno, and Hiroshi Baba, and Kenji Sakimura
March 2011, Anesthesia and analgesia,
Copied contents to your clipboard!